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Perspectives From a Low-Income Setting
abstract
PurposeWilms tumor is thecommonest renalmalignancy inchildhood.Survival inhigh-incomecountries is
approximately 90%, whereas in low-income countries, it is less than 50%. This study assessed treatment
outcomes of patients with Wilms tumor at a Kenyan academic hospital.
Patients and Methods We conducted a retrospective medical record review of all children diagnosed with
Wilms tumor between 2010 and 2012. Data on treatment outcomes and various sociodemographic and
clinical characteristics were collected.
Results Of the39patientswithWilms tumor, 41%hadevent-free survival, 31%abandoned treatment, 23%
died, and 5% had progressive or relapsed disease. Most patients presented at an advanced stage: stage I
(0%), II (7%), III (43%), IV (40%), orV (10%). Themost likely treatment outcome inpatientswith low-stage
(I to III) disease was event-free survival (67%), whereas in those with high-stage (IV to V) disease, it was
death (40%).Nodeathsor instancesof progressiveor relapseddiseasewere recordedamongpatientswith
low-stage disease; their only reason for treatment failure was abandonment of treatment. Stage of disease
significantly affected treatment outcomes (P5 .014) and event-free survival estimates (P < .001). Age at
diagnosis, sex, duration of symptoms, distance to hospital, and health insurance status did not statistically
significantly influence treatment outcomes or event-free survival estimates.
Conclusion Survival of patients with Wilms tumor in Kenya is lower compared with that in high-income
countries. Treatment abandonment is the most common cause of treatment failure. Stage of disease at
diagnosis statistically significantly affects treatment outcomes and survival.
J Glob Oncol 3. © 2016 by American Society of Clinical Oncology Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Wilms tumor is the most common primary renal
malignancy in children. It accounts for 5% of
childhood malignancies.1 It is thought to arise
from nephrogenic rests, which are foci of persis-
tent metanephrenic cells.2 Survival rates have
improved from20% in the 1960s to approximately
90% currently in high-income countries; middle-
income countries have survival rates of approxi-
mately 80%.2,3 This has been achieved through
cooperative study groups as well as use of multi-
modal approaches to therapy. The twomain study
groups that have been involved are the National
Wilms’ Tumor Study Group and the International
Society of Pediatric Oncology (SIOP).2,4,5
Low-income countries, however, have survival
rates between 20% and 50%.1-3 Reasons for the
low survival in low-income countries include lim-
ited access to proper medical care as a result of
lack of facilities for treatment, shortage of person-
nel, long distances to treatment centers, poor
infrastructure, and limited public transport facili-
ties. These factors lead to late presentation, which
also affects outcomes. Other contributors to the
low survival include lack of health insurance,
abandonment of treatment, and lack of a multi-
disciplinary approach to the management of
patients. Treatment includes surgery and che-
motherapy, aswell as radiotherapy formetastatic
disease.2,3,5
The aims of our studywere to assess the treatment
outcomes of children presentingwithWilms tumor
at a Kenyan academic hospital and to evaluate the
influence of various sociodemographic and clini-
cal characteristics (eg, age at diagnosis, sex, du-
ration of symptoms, stage of disease, distance to
hospital, and health insurance status) on treat-
ment outcomes.
PATIENTS AND METHODS
Setting
Kenya is situated inEastAfrica and is a low-income
country with a population of approximately 43 mil-
lion people.6 Most of the population (45%) lives
below thepoverty line.7 This studywascarried out at
Moi Teaching andReferral Hospital (MTRH), which
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is an academic hospital in Eldoret, a town 300 km
northwest of the capital city Nairobi. The hospital
has acapacity of approximately800beds, including
72 beds in the pediatric ward, of which 12 are
dedicated to pediatric oncology.8 Approximately
120 pediatric oncology patients are seen in the
hospital every year, in contrast to the expected
number of 700 patients.8 One pediatrician is in-
volved in the care of oncology patients. Two
pediatric surgeons are involved in the surgical
aspects of care. There is no radiotherapy facility
in Eldoret; patients who require radiotherapy are
referred to a center in Nairobi. Families pay for
their hospital bills throughhealth insuranceor out
of pocket. However, only approximately 10% of
the Kenyan population have health insurance,
which is provided by the government-owned and
-controlled National Hospital Insurance Fund
(NHIF) or through private insurance companies.
Kenyan citizens can enroll with NHIF and pay a set
monthly fee. Payments are dependent on level of
income for those who are formally employed,
whereas those who are self-employed or casual
workerspayamonthly fee of approximatelyUS$12.
NHIF provides cover for inpatient care for the entire
family in government-owned health facilities.9,10
Patients with Wilms tumor are treated according
to a protocol modeled on the SIOP approach.
Treatment is started after imaging via computed
tomography confirms an intrarenal tumor. All pa-
tients receive 6 weeks of preoperative chemother-
apy with vincristine, dactinomycin, and doxorubicin.
Vincristine is administered once per week; dactino-
mycin is administered in weeks 1, 3, and 5; and
doxorubicin is administered in weeks 1 and 5 only.
Patientsare thenscheduledforsurgery inweek7or8
of treatment.Disease staging is performed intraoper-
atively, using imaging to detect lung or liver metas-
tases. Staging guides the decision on postoperative
treatment. Postoperatively, patients with stage I dis-
ease receive 4 weeks of vincristine and dactinomy-
cin. Children with stage II or III disease receive
16 weeks of vincristine and dactinomycin; those
with stage III disease are referred for radiotherapy
as well. Children with stage IV disease, as well as
those with anaplastic histology regardless of stage,
receive vincristine, dactinomycin, and doxorubicin
for 16 weeks. Patients with stage V disease receive
the same preoperative chemotherapy outlined
here; the decision on further treatment depends
on preoperative imaging and findings at surgery.
Study Design
This was a retrospective medical record study. All
children presenting with Wilms tumor at MTRH
between January 1, 2010, and December 31,
2012, age between 0 and 16 years at diagnosis
were included. It is important to note that we did
not select patients for our analysis; rather, we
included all patients who were diagnosed with
Wilms tumor.
The names and inpatient numbers of patients
diagnosed with Wilms tumor were extracted from
the pediatric oncology database. Files were ob-
tained from the medical record department. Soci-
odemographic and clinical characteristics were
Table 1. Patient Sociodemographic and Clinical
Characteristics (N = 39)
Characteristic No. (%)
Age at diagnosis, months
Mean 51
SD 29
Median 53
Range 5-147
Sex
Male 19 (49)
Female 20 (51)
Tribe (n = 37)
Luhya 16 (43)
Kalenjin 10 (27)
Luo 6 (16)
Kikuyu 3 (8)
Teso 1 (3)
Kisii 1 (3)
Distance to MTRH, km
< 100 18 (46)
. 100 21 (54)
Duration of symptoms before first hospital
admission at MTRH (n = 36), months
1-3 24 (67)
. 3 12 (33)
Stage of disease at diagnosis (n = 30)
I 0 (0)
II 2 (7)
III 13 (43)
IV 12 (40)
V 3 (10)
Health insurance status at diagnosis
NHIF 16 (41)
No NHIF 23 (59)
Abbreviations: MTRH, Moi Teaching and Referral Hospital; NHIF,
National Hospital Insurance Fund; SD, standard deviation.
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extracted from patients’ medical records using a
data collection form.
Sociodemographic characteristics includedageat
diagnosis, sex, ethnicity, patient residence, and
enrollment in NHIF. A patient’s residence was
used todetermine thedistance fromMTRH,which
was subsequently categorized into distance of
100 km or less or more than 100 km.
Clinical characteristics included date of diagnosis,
disease stage, time to event, and treatment out-
come. Disease stage was determined using imag-
ing todetect any lungor livermetastases, aswell as
through the information derived from intraopera-
tive findings. For further analysis on outcomes, we
grouped those with nonmetastatic stage I to III
disease into low-stage and those with stage IV or V
disease into high-stage groups. Treatment out-
comes were classified as abandonment of treat-
ment, death, progressive or relapsed disease, and
event-free survival. Abandonment of treatment
was defined as either not starting or not continuing
planned treatment during 4 or more sequential
weeks.11
Data Analysis
Data analysis and management were performed
using SPSS software (version 20; SPSS, Chicago,
IL). Frequency distributions,means, andmedians
were calculated. The relationship between treat-
ment outcomes and sociodemographic or clinical
characteristics was evaluated using x2 and
Fisher’s exact tests. The probability of event-free
survival was estimated using the Kaplan-Meier
method; estimates were compared using the
log-rank test. Event-free survival was measured
from date of Wilms tumor diagnosis to first treat-
ment failure or date of last follow-up. Treatment
failure included abandonment of treatment,
death, and progressive or relapsed disease.
RESULTS
A total of 39 patients with Wilms tumor presented
to the hospital during the study period. Girls com-
prised 52% of patients. Table 1 lists sociodemo-
graphic and clinical characteristics. Almost all
patients (97%) were referred to MTRH from other
health facilities. A majority (91%) were referred
from secondary-level public health facilities,
whereas the rest were referred by private clinics
(3%), private hospitals (3%), or tertiary-level hos-
pitals (3%). Before patients presented to MTRH,
only 16% had received a possible diagnosis of
Wilms tumor, and none had received any treat-
ment specifically for Wilms tumor. A majority of
patients presented at later stages. There was no
patient with stage I disease. Children were diag-
nosed with: stage II (7%), III (43%), IV (40%), or V
(10%) disease.Of the 39patients, 54% livedmore
than 100 km from MTRH. At time of diagnosis,
39% of patients had NHIF. Of those who did not
have NHIF at diagnosis, most (83%) registered
while undergoing treatment atMTRH,bringing the
total enrollment level to 90%.
The overall 3-year survival rate was 41%. Figure 1
shows the event-free survival estimate of all chil-
dren with Wilms tumor.
As summarized in Table 2, the most common
cause of treatment failure was abandonment of
treatment (31%), and the second most common
was death (23%). All deaths occurred within
4months of diagnosis, with 78% of these children
dying within the first 2 months. The least common
cause of treatment failure was progressive or re-
lapsed disease (5%).
Of 30 patients with documented stage of disease,
50% had low-stage (I to III) and 50% had high-
stage (IV to V) disease. The most likely treatment
outcome in patients with low-stage disease was
event-free survival (67%),whereas inpatientswith
high-stage disease, it was death (40%).No deaths
or instances of progressive or relapsed disease
occurred among patients with low-stage disease.
As summarized in Table 2, differences in treat-
ment outcomes between children with low- and
high-stage disease were significant (P 5 .014).
Figure 2 shows that event-free survival estimates
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Fig 1. Kaplan-Meier
estimates of event-free
survival in children with
Wilms tumor (N 5 39).
Events included
abandonment of treatment,
death, and progressive or
relapsed disease. Crosses
indicate censored patients.
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differed significantly between patients with stage
II, III, IV and V disease (P , .001).
Other sociodemographic and clinical characteris-
tics (ie, age at diagnosis, sex, duration of symp-
toms, distance to hospital, and health insurance
status) did not have a statistically significant influ-
ence on treatment outcomes or event-free survival
estimates. Figures 3 and 4 illustrate that living at a
shorter distance from MTRH and having health
insurance at diagnosis led to better chances of
survival, but this did not reach statistical signifi-
cance (P 5 .063 and .358, respectively).
DISCUSSION
This study demonstrated a survival rate of 41%
among patients diagnosed with Wilms tumor at
MTRH between the years 2010 to 2012. This is a
great improvement from the survival rate of 29%
that was documented for those patients treated
at the institution between the years 2000 and
2007.12 This improvement may be attributed to
several factors. The hospital adopted the SIOP
approach to the management of Wilms tumor
during the timeframe of our study. In the previous
study, some patients never received any preoper-
ative chemotherapy, and mortality was high. In
2009, the hospital developed a protocol manual
that was used to manage all patients with cancer.
Use of protocols and establishment of a multidis-
ciplinary team have been demonstrated to lead to
better outcomes. We now have competent pedi-
atric surgeons, psychological counselors, social
workers, andpharmacists involved in the care of
patients with Wilms tumor. A team of dedicated
pediatric oncology nurses cares for the chil-
dren, unlike in the past, when nurses were
moved from the department every few months.
This has increased nurses’ knowledge and ex-
perience, which has resulted in better patient
Table 2. Treatment Outcomes in Children With Wilms Tumor and Influence of Disease Stage, Distance to Hospital, and
HealthI Insurance Status (N = 39)
Factor
Outcome, No. (%)
TreatmentAbandonment Death Progressive or Relapsed Disease Event-Free Survival
Overall patient population 12 (31) 9 (23) 2 (5) 16 (41)
Disease stage (n = 30)
Low* 5 (33) 0 (0) 0 (0) 10 (67)
High† 3 (20) 6 (40) 1 (7) 5 (33)
P .014
Distance to hospital, km
< 100 4 (22) 2 (11) 2 (11) 10 (56)
. 100 8 (38) 7 (33) 0 (0) 6 (29)
P .074
Health insurance status
NHIF 4 (25) 4 (25) 0 (0) 8 (50)
No NHIF 8 (35) 5 (22) 2 (9) 8 (35)
P .640
Abbreviation: NHIF, National Hospital Insurance Fund.
*Low indicates stage I to III disease.
†High indicates stage IV to V disease.
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Fig 2. Kaplan-Meier
estimates of event-free
survival in children with
Wilms tumor per disease
stage at diagnosis (P ,
.001). Events included
abandonment of treatment,
death, and progressive or
relapsed disease. Crosses
indicate censored patients.
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care. Supportive care has also improved over
time through use of a protocol for management
of febrile neutropenia and better availability of
antibiotics. Nutritional care has improved sig-
nificantly. Previously, cultural beliefs and asso-
ciations with death prevented both the medical
team and the families from using nasogastric
feeding. Now most children do undergo naso-
gastric tube feeding, which allows feeding even
when children have decreased appetite or
mucositis. All patients were also actively en-
couraged to register with NHIF and were pro-
vided with assistance whenever possible. All
these interventions have been achieved through
collaboration with two partners in high-income
countries: the Indiana University School of Medi-
cine in the United States and the Vrije Universiteit
Medical Center in the Netherlands. This collabora-
tion has led to the transfer of knowledge among
physicians,nurses,andothersupportstaff,achieved
through exchange visits, teleconferences in which
patient care is discussed, and training workshops
held in Eldoret every year.
High-income countries have reported high sur-
vival ratesamongchildrenwithWilms tumor. In the
United Kingdom, an overall survival rate of 88%
was documented on 10-year follow-up.13 Middle-
income countries also have good survival rates,
with China reporting a survival rate of 81%.14
However, the survival rates are still low in low-
income countries, especially in Africa. A 2-year
survival rate of 25% was reported from an eight-
center Wilms tumor treatment collaborative effort
in Africa.15 In Malawi, the survival rate is 46%.16
These low survival rates have been attributed to
several factors, including high treatment aban-
donment and treatment-related mortality.17
The rate of treatment abandonment was 31% in
our study. This is a decrease from the 54% aban-
donment rate that we reported before in the same
hospital for the period of 2007 to 2009, although
the latter study examined all types of cancer.18
This figure is also lower than the 42% reported
previously among patients withWilms tumor at the
same institution.12 In a study that examined sev-
eral hospitals in Kenya, a 50% rate of patients lost
to follow-upwas reportedamong thosewithWilms’
tumor, although this included both patients who
abandoned therapy as well as patients who were
lost to follow-up after finishing treatment.19 In
Africa,Wilms tumor treatment abandonment rates
vary between 14% and 48%.15 Abandonment in
this setting is attributed to a lack of parental
education on Wilms tumor by medical staff, par-
ents’ misunderstanding of treatment protocols,
and families’ financial difficulties.20 Abandon-
ment of therapy contributes to a large extent to
poor outcomes in pediatric oncology in low-
income countries. In our study, abandonment
was the only adverse outcome among those pa-
tients with stage II or III disease. If this phenom-
enon is addressed adequately, survival in this
group could improve, approaching that reported
in high-income countries.
A majority of patients of our study presented with
late-stage disease. Thosewho had stage II disease
had good outcomes, in contrast to those with later
stages of disease. A multicenter study of Wilms
tumor involving French-speaking countries in
Africa reported that patients with stage III or IV
disease comprised 41% of all patient cases.17 In
South Africa, those with stage III or IV disease
comprised 49% of patient cases.21 In both these
studies, patients with stage V disease were ex-
cluded from analysis. This indicates that late pre-
sentation is still a major issue in low-income
settings. It could possibly be explained by circum-
stances that lead to both patient and health care
system delays. Patient delays usually result from
outdated health beliefs, poor reputation of public
hospitals, preference for alternativemedicine, and
financial difficulties coupled with lack of health
insurance. Health care system delays result from
unavailability of the qualified personnel or equip-
ment required to make correct diagnoses.22,23
Disease stage has been documented as one of
the most important prognostic factors. However,
there are still huge differences when we compare
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outcomes inhigh- versus low-incomecountries. In
the United Kingdom, an overall survival rate of
81% for stage IV diseasewas reported.13 In Africa,
in the French-speaking collaborative group, chil-
dren with stage IV disease had an overall survival
rate of 49%, and in South Africa, the survival rate
was 57%.15,21 Disparities in survival between
high- and low-income countries are worse in
the more advanced disease stages; however,
most patients from low-income countries present
with advanced disease. Therefore, to improve out-
comes, we should concentrate not only on improv-
ing the standards of care but also on diagnosing
patientswithearly-stagedisease. Increasingaware-
ness of childhood cancer among health care
workers is paramount. Having ultrasoundmachines
as well as trained personnel in most primary care
centers could lead to increased detection rates. This
strategy could have the potential of increasing sur-
vival with less strain on the health care system.
Patients living more than 100 km fromMTRH had
lower chances of survival compared with those
living nearer to the hospital, although this did not
reach statistical significance. Themost likely treat-
ment outcome in patients within 100 km ofMTRH
was event-free survival, whereas in patients living
farther from MTRH, it was abandonment of treat-
ment. Distance and transport costs have been
demonstrated to increase chances of abandon-
ment and thereby decrease survival in pediatric
oncology.24,25 In a previous study among families
of children with cancer who abandoned treatment
at MTRH, it was found that long distance to the
hospital led to higher costs of transportation and
affected the ability to keep appointments.18 Most
Kenyan families use public transport to reach
MTRH. However, Kenyan public transport is not
well organized. The number and quality of roads
are limited. There are no fixed routes, timetables,
or fares.18 These infrastructural obstacles may
ultimately affect the survival of childrenwithWilms
tumor.
Although only 39% of families had health insur-
ance before coming to MTRH, this number is
higher than the national figure of 10%.26 Previous
studies in the Kenyan setting have shown that
having NHIF at diagnosis significantly decreases
abandonment and improves childhood cancer
survival.18,20 This taught our team that it is impor-
tant to enroll patients in NHIF. In the pediatric
oncology ward at MTRH, the physicians and
nurses therefore now continually inform families
about the need for NHIF. Particularly for children
with potentially good prognoses, like those with
Wilms tumor,medical staffmake sure that families
get NHIF. Support staff help families to collate all
documents required for this purpose and direct
them on which office to visit. Most families in our
study subsequently enrolled in NHIF during hos-
pitalization. This illustrates that if families are given
the right information and are assisted in obtaining
health insurance, many of them are willing to do
so. The government should have mass media
educational campaigns on the benefits and pro-
cedures of registering with NHIF.
The main limitations in this study were the small
sample size and the fact that, because it was a
retrospective medical record review, some data
were missing. In conclusion, the survival rate of
patients with Wilms tumor at MTRH improved
between the years 2010 and 2012 as compared
with 2000 to 2007. Themain reason for treatment
failure was abandonment of treatment. Disease
stage at diagnosis significantly affected treatment
outcomes and event-free survival estimates. Age
at diagnosis, sex, duration of symptoms, distance
to hospital, and having health insurance at di-
agnosis did not predict survival.
On the basis of the findings of our study, we
acknowledge that abandonment of treatment
needs to be addressed. Providing proper parental
education and financial support would be useful
strategies. To help reduce the number of children
presenting with late-stage disease and improve
access to conventional health care facilities, we
recommend that the government initiate manda-
tory universal health insurance coverage. Health
care workers should be trained on the clinical
features of Wilms tumor. This should be done by
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incorporating training on childhood cancers into
the curricula of medical training institutions, as
well as through continuous professional develop-
ment for those who have already graduated. To
reduce transportation difficulties for families living
far from the hospital, establishing satellite clinics
and family guesthouses near the hospital could
be beneficial. Ultimately, all these interventions
could improve survival of children with Wilms
tumor.
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